NCT00500721已完成1 期
An Open-Label, Single-Dose Desipramine, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2007年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Pharmacokinetic (PK)
研究概览
简要总结
To evaluate the potential pharmacokinetic (PK) interaction of multiple oral doses of HCV-796 and a single dose of desipramine when coadministered to healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG.
排除标准
- 未提供
结局指标
主要结局
Pharmacokinetic (PK)
时间窗: 21 days
次要结局
- Safety(29 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
HCV-796 and Midazolam Drug Interaction Study in Healthy SubjectsHealthyNCT00410254Wyeth is now a wholly owned subsidiary of Pfizer38
已完成
1 期
Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy AdultsHepatitis CHepatic InsufficiencyNCT00314054Wyeth is now a wholly owned subsidiary of Pfizer27
已完成
1 期
A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive PatientsHepatitis CNCT00445315Pfizer32
已完成
1 期
CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)Central Nervous System DiseasesNCT03569579Chong Kun Dang Pharmaceutical20
已完成
1 期
Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)Hepatitis CNCT02269059Merck Sharp & Dohme LLC13